



Addex Pharmaceuticals

First Half 2011 Financial Results

July 27, 2011

Disclaimer

These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.

These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Pharmaceuticals Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Pharmaceuticals Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Pharmaceuticals Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

These materials are strictly confidential and must not be disclosed or distributed to third parties.

Corporate overview

- Focused on the development of allosteric modulators
- Proprietary discovery platform
 - 70,000+ compound allostery-biased library
 - Patented high throughput screening/optimisation systems
- Collaborations with Merck and J&J
- Lead compounds: dipraglurant-IR & ADX71149
 - Dipraglurant-IR Phase IIa PD-L1D started 1Q11
 - Study supported by Michael J. Fox Foundation for Parkinson's Research
 - Data 1H12
 - OMJPI started ADX71149 Phase IIa schizophrenia study 1Q11

Pipeline

Partner	Molecule / Mechanism	Assay Development & Screening	Preclinical			Clinical		
			Hit-to-Lead	Lead Optimization	Clinical Candidate	Phase I	Phase IIa	Milestone
	Dipraglurant-IR (ADX48621) mGluR5 NAM	Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID) partially funded by The Michael J. Fox Foundation						Ph II data 1H12
	Dipraglurant-ER (ADX48621) mGluR5 NAM	Dystonia						
Janssen Pharmaceuticals, Inc.	ADX71149 mGluR2 PAM	Schizophrenia funded & developed by JPI*						
		Anxiety						
	FSHR/LHR NAM	Endometriosis						
	GABA-BR PAM	Pain						
	mGluR2 NAM	Alzheimer's / Depression						
Merck & Co., Inc.	mGluR4 PAM	Parkinson's Disease ‡						CNS
	mGluR7 NAM	Depression Generalized Anxiety Disorder						
	mGluR5 PAM	Schizophrenia ‡						
	Receptor tyrosine kinase superfamily (TrkB)	Neurodegenerative & other diseases						
	GLP1R PAM	Type II Diabetes						Metabolism & Inflammation
	TNF receptor superfamily (TNFR1 NAM)	Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease Alzheimer's, Multiple Sclerosis						
	A2A PAM	Psoriasis, Osteoarthritis						
	Interleukin receptor family (IL-1R1 NAM)							

NAM = negative allosteric modulator (an inhibitor)
PAM = positive allosteric modulator (an activator)

‡ and undisclosed additional indications

* Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Financial Highlights

- Cash used: CHF13.6 million (in line with guidance)
- Cash as of June 30, 2011: CHF50.2 million
(31/12/2010: CHF63.8m)
- Income: CHF3.2 million
(H1 2010: CHF2.7m)
- Net loss reduced by 14% to CHF14.6 million
(H1 2010: CHF17.3m)
- Headcount: 111.8 FTE as of June 30, 2011

First Half 2011

Consolidated Balance Sheets

In CHF thousands	Jun 30, 2011	Dec 31, 2010	Comments
Cash and cash equivalents	50'230	63'797	Cost of operations
Other current assets	2'838	2'698	Prepayments
Property, plant and equipment	5'411	6'668	Annual depreciation charge; no significant capex in H1 2011
Other non-current assets	1'065	1'121	Lease guarantee, employee loans & intangibles
Total assets	59'544	74'284	
Payables and accruals	8'672	8'982	Primarily staff costs & clinical costs
Deferred income	273	295	Merck agreement & MJFF installments
Non-current liabilities	785	593	IAS 19 pension obligation
Shareholders' equity	49'814	64'414	Net loss
Total liabilities & s/holders' equity	59'544	74'284	

First Half 2011

Consolidated Income Statements


In CHF thousands	H1 2011	H1 2010	Var.(%)	Comments
Revenue from collaborations	2'721	1'056	257%	€2M Phase 2 start milestone from OMJP & Merck mGluR4PAM fees
Other income	452	1'644	(73%)	2011 French research tax credit & MJFF grant
Total income	3'173	2'700	18%	
R&D expenses	(14'558)	(16'686)	(13%)	Reduced headcount
G&A expenses	(3'299)	(3'289)	-	Reduced headcount offset by certain restructuring provisions
Operating loss	(14'684)	(17'275)	(15%)	
Finance result, net	(143)	13	-	Interest income offset by financial exchange differences (EUR/CHF)
Net loss for the period	(14'827)	(17'262)	(14%)	
Basic and diluted loss per share (CHF)	(2.07)	(3.01)	(31%)	

First Half 2011

Consolidated Cash Flow Statements

In CHF thousands	H1 2011	H1 2010	Var.(%)	Comments
Cash at beginning of the period	63'797	76'560	(17%)	
Cash used in operating activities	(15'718)	(19'987)	(21%)	Cost of 2011 operations
Cash from collaborations	2'563	485	428%	EUR2M Phase 2 start milestone from OMJP
Cash used in investing activities	(23)	(222)	(90%)	Reduced investment PPE
Cash used in financing activities	(171)	(7)	-	Cost of share capital issuance
Net cash used	(13'349)	(19'731)	(32%)	
Exchange loss on cash	(218)	(142)	54%	Strength of CHF vs EUR
Cash at end of the period	50'230	56'687	(11%)	

Headcount Development



Comments

- YoY headcount reduction of 17% (23.2 FTE)
- Restructuring expected to result in a headcount of 82 FTE by 30th September

Financial Outlook

- 2011 cash utilization guidance of CHF28-32 million
- Cash reach extended from Q1 2013 to Q4 2013
 - Assumption: no cash flows from new partnerships or contingent milestones under existing agreements
- Impact of restructuring:
 - One off charge in H2 2011 of CHF1.7m
 - Annual savings of CHF8m per year starting in 2012

allosteric modulators for human health

tell us which targets interest you !

www.addexpharma.com